• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Misleading congress about drug development: Reply.

作者信息

Dimasi Joseph A, Hansen Ronald W, Grabowski Henry G

机构信息

Tufts University.

出版信息

J Health Polit Policy Law. 2008 Apr;33(2):319-24; discussion 325-7. doi: 10.1215/03616878-2007-063.

DOI:10.1215/03616878-2007-063
PMID:18325904
Abstract

The review essay by Donald Light about a Congressional Budget Office report on pharmaceutical research and development (R&D) (Light 2007) contains factual errors, leaves the reader uninformed about rebuttal responses to criticisms made in the review about studies of R&D costs, and draws erroneous conclusions about the nature of industry economics.

摘要

相似文献

1
Misleading congress about drug development: Reply.
J Health Polit Policy Law. 2008 Apr;33(2):319-24; discussion 325-7. doi: 10.1215/03616878-2007-063.
2
America's other drug problem: how the drug industry distorts medicine and politics.美国的另一个毒品问题：制药行业如何扭曲医学与政治。
New Repub. 2002 Dec 16;227(25):27-41.
3
Congress has its brain on drug benefits.
Fortune. 2003 Jan 20;147(1):178.
4
The economics of priority review vouchers.优先审评券的经济学。
Drug Discov Today. 2010 Nov;15(21-22):887-91. doi: 10.1016/j.drudis.2010.08.008. Epub 2010 Aug 21.
5
The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.药物研发的经济学以及药物疗法在市场中的最终估值。
Clin Pharmacol Ther. 2008 Aug;84(2):263-6. doi: 10.1038/clpt.2008.117. Epub 2008 Jun 11.
6
The state of innovation in drug development.药物研发中的创新状况。
Clin Pharmacol Ther. 2008 Feb;83(2):227-30. doi: 10.1038/sj.clpt.6100479.
7
US presidential candidates diverge on how to help biopharma.美国总统候选人在如何帮助生物制药行业的问题上存在分歧。
Nat Med. 2012 Oct;18(10):1445. doi: 10.1038/nm1012-1445.
8
In search of sustainability: process R&D in light of current pharmaceutical industry challenges.探寻可持续性：鉴于当前制药行业的挑战进行工艺研发。
Drug Discov Today. 2006 Nov;11(21-22):966-74. doi: 10.1016/j.drudis.2006.09.012. Epub 2006 Sep 26.
9
Deals landscape: notable deals in the pharmaceutical industry in the first quarter of 2008.交易概况：2008年第一季度制药行业的重大交易
IDrugs. 2008 May;11(5):351-5.
10
GAO report says drug R & D costs rising, innovation decreasing.美国政府问责局报告称，药品研发成本上升，创新能力下降。
Consult Pharm. 2007 Mar;22(3):257-8.

引用本文的文献

1
How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment.研究和开发一种新药需要多少钱？系统评价和评估。
Pharmacoeconomics. 2021 Nov;39(11):1243-1269. doi: 10.1007/s40273-021-01065-y. Epub 2021 Aug 9.
2
The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation.
Pharmacoeconomics. 2015 Jul;33(7):749-63. doi: 10.1007/s40273-015-0300-0.
3
The opportunity cost of capital: development of new pharmaceuticals.资本的机会成本：新药品的研发
Inquiry. 2015 May 1;52. doi: 10.1177/0046958015584641. Print 2015.
4
Lack of adequate appreciation of physical exercise's complexities can pre-empt appropriate design and interpretation in scientific discovery.对体育锻炼复杂性缺乏充分认识，可能会妨碍科学发现中适当的设计和解释。
J Physiol. 2009 Dec 1;587(Pt 23):5527-39. doi: 10.1113/jphysiol.2009.179507. Epub 2009 Sep 1.